Despite significant advancements in global oncology care, many U.S. Food and Drug Administration (FDA) approved drugs with high European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMOMCBS) scores are unavailable in India. These drugs have the potential to revolutionize cancer treatment, but face challenges related to regulatory frameworks, economic barriers, insurance coverage, and healthcare infrastructure. This article explores these barriers and their impact on cancer healthcare in India while proposing actionable solutions to address them.
Mehta et al. (Mon,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: